Maravai LifeSciences (NASDAQ: MRVI) revenue
Maravai LifeSciences reported revenue of $185.7m for fiscal 2025, 28.3% less than in fiscal 2024 ($259.2m). Since fiscal 2020 its revenue has fallen by 34.6%, an average decline of 8.1% a year.
Maravai LifeSciences's revenue has fallen for 3 years in a row, and its best year of the last 6 was fiscal 2022. The biggest drop was in fiscal 2023, −67.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $185.7m | −28.3% | −$215.3m | −115.9% |
| 2024 | $259.2m | −10.3% | −$235.6m | −90.9% |
| 2023 | $288.9m | −67.3% | −$31.6m | −11.0% |
| 2022 | $883.0m | +10.5% | $574.2m | 65.0% |
| 2021 | $799.2m | +181.3% | $554.6m | 69.4% |
| 2020 | $284.1m | — | $119.9m | 42.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Maravai LifeSciences revenue compared with its sector
By revenue for its latest fiscal year, Maravai LifeSciences ranks 253rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Maravai LifeSciences, −28.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 251st | Cronos Group | $193.4m | 19.5% |
| 252nd | Rhythm Pharmaceuticals | $189.8m | 45.8% |
| 253rd | Maravai LifeSciences | $185.7m | −28.3% |
| 254th | Stoke Therapeutics | $184.4m | 404.5% |
| 255th | Phathom Pharmaceuticals | $175.1m | 216.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Maravai LifeSciences
- How much revenue did Maravai LifeSciences make in fiscal 2025?
- Maravai LifeSciences reported revenue of $185.7m for fiscal 2025, compared with $259.2m in fiscal 2024.
- How much has the revenue of Maravai LifeSciences fallen?
- Between fiscal 2020 and fiscal 2025 it went from $284.1m to $185.7m: 34.6% less, an average decline of 8.1% a year.
- What was the best year for revenue at Maravai LifeSciences?
- Of its last 6 fiscal years, fiscal 2022, with $883.0m.
- Where does Maravai LifeSciences rank in its sector by revenue?
- It ranks 253rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Maravai LifeSciences come from?
- From the annual report (Form 10-K) that Maravai LifeSciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Maravai LifeSciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Maravai LifeSciences: the Maravai LifeSciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.